A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Purpose

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

Condition

  • Myelofibrosis (MF)

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Participants with documented diagnosis of intermediate-2 or high-risk primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. - Participant must be ineligible or unwilling to undergo stem cell transplantation at time of study entry. - Eastern Cooperative Oncology Group (ECOG) of 0,1, or 2. - Participant must have either received prior treatment with ruxolitinib OR another Janus Kinase 2 (JAK-2) inhibitor therapy OR must not have received any prior treatment with JAK-2 inhibitor or BET inhibitor. - Participant has splenomegaly as defined in the protocol. - Participant must meet the laboratory parameters (adequate bone marrow, renal and hepatic function) as defined in the protocol.

Exclusion Criteria

  • Splenic irradiation within 6 months prior to screening, or prior splenectomy. - Leukemic transformation (> 10% blasts in peripheral blood or bone marrow biopsy). - Participant is currently on medications that interfere with coagulation (including warfarin) or platelet function with the exception of low dose aspirin (up to 100 mg) and Low-molecular-weight heparin. - Prior therapy with a BH3 mimetic compound. - Participant has received strong or moderate CYP3A inhibitors within 14 days prior to the administration of the first dose of navitoclax.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Navitoclax + ruxolitinib 		Participants will be administered navitoclax once daily (QD) at various doses and a dose greater than or equal to 10 mg of ruxolitinib twice daily (BID).
  • Drug: Ruxolitinib
    Tablet; Oral
    Other names:
    • Jakafi
  • Drug: Navitoclax
    Tablet; Oral
    Other names:
    • ABT-263
Experimental
Navitoclax 		Participants will be administered various doses of navitoclax once daily (QD)
  • Drug: Ruxolitinib
    Tablet; Oral
    Other names:
    • Jakafi
  • Drug: Navitoclax
    Tablet; Oral
    Other names:
    • ABT-263

Recruiting Locations

UAB Comprehensive Cancer Cente /ID# 165464
Birmingham, Alabama 35217

More Details

Status
Recruiting
Sponsor
AbbVie

Study Contact

ABBVIE CALL CENTER
847.283.8955
abbvieclinicaltrials@abbvie.com